PortalPublikationenAnwendung und Nutzen kardialer Biomarker in der Praxis

Anwendung und Nutzen kardialer Biomarker in der Praxis

Standard

Anwendung und Nutzen kardialer Biomarker in der Praxis. / Brunner, F. J.; Blankenberg, S.

in: KARDIOLOGE, Jahrgang 7, Nr. 5, 10.2013, S. 377-386.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung

Harvard

Brunner, FJ & Blankenberg, S 2013, 'Anwendung und Nutzen kardialer Biomarker in der Praxis', KARDIOLOGE, Jg. 7, Nr. 5, S. 377-386. https://doi.org/10.1007/s12181-013-0500-9

APA

Brunner, F. J., & Blankenberg, S. (2013). Anwendung und Nutzen kardialer Biomarker in der Praxis. KARDIOLOGE, 7(5), 377-386. https://doi.org/10.1007/s12181-013-0500-9

Vancouver

Brunner FJ, Blankenberg S. Anwendung und Nutzen kardialer Biomarker in der Praxis. KARDIOLOGE. 2013 Okt;7(5):377-386. https://doi.org/10.1007/s12181-013-0500-9

Bibtex

@article{966c905a1f2347cbb7c0e32e58e720be,
title = "Anwendung und Nutzen kardialer Biomarker in der Praxis",
abstract = "For the application of biological markers in the clinical routine a benefit in the diagnosis of acute and chronic cardiac diseases is well known. Currently, the use of cardiac troponins to identify patients with acute non-ST-segment elevation myocardial infarction is well established. Furthermore, the quantification of natriuretic peptides can be used for the exclusion of acute and chronic heart failure. Additionally, the possible implementation of biological markers in the individual risk prediction is under investigation. Further studies need to be carried out to show whether the use of different biological markers could lead to a better treatment in a primary or secondary preventive setting. Due to the development of new assays detection of cardiac troponin levels at a very low concentration is possible. In the future the detection of these low troponin concentrations could become a diagnostic benefit for cardiovascular risk prediction.",
keywords = "Cardiac troponin, Heart failure, Myocardial infarction, Natriuretic peptide, Prevention",
author = "Brunner, {F. J.} and S. Blankenberg",
year = "2013",
month = oct,
doi = "10.1007/s12181-013-0500-9",
language = "Deutsch",
volume = "7",
pages = "377--386",
journal = "KARDIOLOGE",
issn = "1864-9718",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Anwendung und Nutzen kardialer Biomarker in der Praxis

AU - Brunner, F. J.

AU - Blankenberg, S.

PY - 2013/10

Y1 - 2013/10

N2 - For the application of biological markers in the clinical routine a benefit in the diagnosis of acute and chronic cardiac diseases is well known. Currently, the use of cardiac troponins to identify patients with acute non-ST-segment elevation myocardial infarction is well established. Furthermore, the quantification of natriuretic peptides can be used for the exclusion of acute and chronic heart failure. Additionally, the possible implementation of biological markers in the individual risk prediction is under investigation. Further studies need to be carried out to show whether the use of different biological markers could lead to a better treatment in a primary or secondary preventive setting. Due to the development of new assays detection of cardiac troponin levels at a very low concentration is possible. In the future the detection of these low troponin concentrations could become a diagnostic benefit for cardiovascular risk prediction.

AB - For the application of biological markers in the clinical routine a benefit in the diagnosis of acute and chronic cardiac diseases is well known. Currently, the use of cardiac troponins to identify patients with acute non-ST-segment elevation myocardial infarction is well established. Furthermore, the quantification of natriuretic peptides can be used for the exclusion of acute and chronic heart failure. Additionally, the possible implementation of biological markers in the individual risk prediction is under investigation. Further studies need to be carried out to show whether the use of different biological markers could lead to a better treatment in a primary or secondary preventive setting. Due to the development of new assays detection of cardiac troponin levels at a very low concentration is possible. In the future the detection of these low troponin concentrations could become a diagnostic benefit for cardiovascular risk prediction.

KW - Cardiac troponin

KW - Heart failure

KW - Myocardial infarction

KW - Natriuretic peptide

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=84892947228&partnerID=8YFLogxK

U2 - 10.1007/s12181-013-0500-9

DO - 10.1007/s12181-013-0500-9

M3 - SCORING: Zeitschriftenaufsatz

AN - SCOPUS:84892947228

VL - 7

SP - 377

EP - 386

JO - KARDIOLOGE

JF - KARDIOLOGE

SN - 1864-9718

IS - 5

ER -